Study of the effectiveness of Moxifloxacin in experimental colibacteriosis of laboratory animals

Strains of Escherichia coli isolated from animals are commensal microorganisms, still some E. coli serotypes can cause pathology in animals. Accordingly new methods of treating colibacillosis are in demand. The goal of the present study was to determine the effectiveness of moxifloxacin for treatment of white mice, experimentally infected with E. coli. The drug was administered to laboratory animals intraperitoneally at a dose 20 mg per kg of body weight once a day and twice a day in the course of 1, 3, 5, 7 and 10 days. We found out that even a single administration of moxifloxacin makes it possible to achieve reliably better results, as compared to the control group. We also noted that the effectiveness of the administered drug was correspondent to the duration of treatment and the frequency of administration on days 1, 2 and 3 of the treatment. When treatment lasts one day moxifloxacin has low activity with single administration and it is active with two administrations per day. When treatment lasts 3 days the drug can be considered active with either method of administration, though the effectiveness of moxifloxacin and survivability of mice are reliably higher with 2 administrations per day. Maximum effectiveness was achieved when moxifloxacin was administered for 5, 7 and 10 days (active and highly active). Statistical analysis of the data obtained showed that frequency of administration on days 5 to 10 had little effect on the effectiveness of the drug. The differences between the respective groups were minimal and statistically unreliable. Our research demonstrated clearly the fact that in order to design new effective regimens of moxifloxacin for treating colibacillosis one must study characteristics of its pharmacokinetics.

1. Tenaillon, O., Skurnik, D., Picard, B. et al. The population genetics of commensal Escherichia coli. Nat Rev Microbiol 8, 207–217 (2010). https://doi.org/10.1038/nrmicro2298

2. Braz VS, Melchior K, Moreira CG. Escherichia coli as a Multifaceted Pathogenic and Versatile Bacterium. Front Cell Infect Microbiol. 2020 Dec 21; 10:548492. doi: 10.3389/fcimb.2020.548492. PMID: 33409157; PMCID: PMC7779793.

3. Kaper, J., Nataro, J. & Mobley, H. Pathogenic Escherichia coli. Nat Rev Microbiol 2, 123–140 (2004). https://doi.org/10.1038/nrmicro818.

4. Zhdanova I.N. Kolibakterioz krupnogo rogatogo skota v Permskom kraie: rasprostranennost’, istochniki vozbuditelia i ego biologicheskiie osobennosti [Cattle colibacillosis in Perm krai: prevalence, sources of the causative agent and its biological characterization] / I.N. Zhdanova, V.V. Mokrushin, M.V. Kuznetsova // Sel’skokhozyaistvennaya biologiya [Agricultural Biology], 2022, V. 57, no. 4, pp. 776-790. – Doi: 10.15389/agrobiology.2022.4.776rus (In Russ.)

5. Yurin D.V. Chuvstvitel’nost’ vozbuditelei bakterial’nykh boleznei zhivotnykh k tsiprofloksatsinu [Sensitivity of infection agents of bacterial animal diseases to ciprofloxacin] / D.V. Yurin, V.N. Skvortsov, A.A. Balbutskaya, S.S. Belimova // Mezhdunarodnyi vestnik veterinarii [International Bulletin of Veterinary Medicine], 2019, no. 1, pp. 91-95. (In Russ.)

6. Mazur A.D. Ostraia tokichnost’ i sravnitel’naia terapevticheskaia effektivnost’ levoflokatsina pri eksperimental’nom kolibakterioze tsypliat [Acute toxicity and comparative therapeutic efficacy of levofloxacin in experimental colibacillosis of chickens] / A.D. Mazur, D.V. Yurin, V.N. Skvortsov, Yu.V. Tarasova // Mezhdunarodnyi vestnik veterinarii [International Bulletin of Veterinary Medicine], 2020, no. 3, pp. 89-93. – DOI: 10.17238/issn2072-2419.2020.3.89. (In Russ.)

7. Mazur A.D. Effektivnost’ levofloksatsina pri eksperimental’nom kolibakterioze laboratornykh zhivotnykh i tsipliat [Effectiveness of levofloxacin in experimental colibacillosis of laboratory animals and chickens] / A.D. Mazur, V.N. Skvortsov, D.V. Yurin, A.A. Moiseeva // Mezhdunarodnyi vestnik veterinarii [International Bulletin of Veterinary Medicine], 2021, no. 1, pp. 62-65. – DOI: 10.17238/issn2072-2419.2021.1.62. (In Russ.)

8. Mazur A.D. Otsenka lechebnoprofilakticheskoi effektivnosti levofloksatsina pri eksperimental’nom kolibakterioze tsypliat v zavisimosti ot zarazhaiushchei dozy [Evaluation of therapeutic and prophylactic effectiveness of levofloxacin in experimental colibacillosis of chickens with regard to infecting dose] / A.D. Mazur, V.N. Skvortsov, D.V. Yurin, A.S. Gorbaneva // Mezhdunarodnyi vestnik veterinarii [International Bulletin of Veterinary Medicine], 2022, no. 2, pp. 64-68. – DOI: 10.52419/issn2072-2419.2022.2.64. (In Russ.)

9. Mazur A.D. Otsenka khimioterapevticheskogo deistviia lekarstvennogo sredstva na osnove levofloksatsina pri eksperimental’nom kolibakterioze tsypliat [Evaluation of the chemotherapeutic effect of a drug based on levofloxacin in experimental colibacteriosis of chickens] / A.D. Mazur, V.N. Skvortsov, D.V. Yurin, A.R. Kravtsova // Mezhdunarodnyi vestnik veterinarii [International Bulletin of Veterinary Medicine], 2024, no. 2, pp. 42-48. – DOI: 10.52419/issn2072-2419.2024.2.42. (In Russ.)

10. Khabriev R.U. Rukovodstvo po eksperimental'nomu (doklinicheskomu) izucheniiu novykh farmakologicheskikh veshchestv. [Handbook of experimental (pre-clinical) study of new pharmacological substances] / Pod obshchei redaktsiei chlenakorrespondenta RAMN, professora R.U. Khabrieva. 2 izd., pererab. i dop. [R.U. Khabriev, professor, corresponding member of Russian Academy of Medical Sciences, Editor-in-Chief, Second Edition, Revised & Expanded]. Moscow, Meditsina Publ., 2005, 832 p. (In Russ.)